Format

Send to

Choose Destination
Aliment Pharmacol Ther. 2018 Mar;47(5):581-587. doi: 10.1111/apt.14479. Epub 2017 Dec 19.

Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.

Author information

1
Department of Internal Medicine I, University Hospital Schleswig-Holstein, Luebeck, Germany.
2
Asklepios Westklinikum Hamburg, Hamburg, Germany.
3
Gastroenterology Opernstraße, Kassel, Germany.
4
Department of Internal Medicine IV (Gastroenterology, Hepatology, Infectious Diseases), University Hospital Jena, Jena, Germany.
5
Practice for Digestive and Metabolic Diseases, Leipzig, Germany.
6
Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
7
Department of Internal Medicine I, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
8
Department of Gastroenterology, University Hospital of Dresden, Dresden, Germany.
9
Department of Internal Medicine, Hospital Waldfriede, Berlin, Germany.
10
Practice of Internal Medicine, Oldenburg, Germany.

Abstract

BACKGROUND:

The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%-15% develops chronic antibiotic-dependent or refractory pouchitis which is usually hard to treat.

AIM:

To evaluate the effectiveness of vedolizumab in patients with chronic pouchitis.

METHODS:

Patients with chronic antibiotic-dependent or refractory pouchitis were treated with vedolizumab (300 mg at week 0, 2, 6 and 10) in 10 IBD centres and retrospectively registered. Data were recorded until week 14 of vedolizumab treatment. In total 20 patients (12 male, median age 43 years) were included for analysis. The effectiveness was measured using the Oresland Score (OS) at week 2, 6, 10 and 14 and the pouch disease activity index (PDAI) at week 0 and 14.

RESULTS:

The mean OS declined from 6.8 (range 2-12) to 3.4 (range 0-11). Concordantly, the mean PDAI after 14 weeks of treatment dropped from 10 (range 5-18) to 3 (range 0-10). Only three patients reported moderate side effects. No serious side effects were recorded. In addition, symptomatic co-medication such as loperamide and tincture of opium could be terminated in 8 out of 12 patients as well as antibiotic treatment could be stopped in 17 out of 19 patients.

CONCLUSION:

Our data indicate that vedolizumab could be an option in the treatment of patients with chronic, antibiotic-dependent or refractory pouchitis.

PMID:
29266360
DOI:
10.1111/apt.14479

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center